| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G79-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G79-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G79-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate |
1994-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1997-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H09500132-A |
| titleOfInvention |
Hydrogel microencapsulated vaccine |
| abstract |
(57) [Summary]nWater soluble polymers or polymer hydrogels are used to encapsulate the antigen for vaccine formation. The antigen is mixed with the polymer solution, the microparticles are formed from the polymer and the antigen, and optionally the polymer is optionally crosslinked to form stable microparticles. The preferred polymers are alginates and polyphosphazenes, as well as mixtures thereof. For oral delivery, the ultrafine particles are preferably 15 microns or less in diameter and adhere to the mucosal lining of the gastrointestinal tract to increase absorption by reticuloendothelial cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001524509-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9526699-B2 |
| priorityDate |
1993-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |